CA3235992A1 - Substituted phenylpropionic acid derivative and use thereof - Google Patents

Substituted phenylpropionic acid derivative and use thereof Download PDF

Info

Publication number
CA3235992A1
CA3235992A1 CA3235992A CA3235992A CA3235992A1 CA 3235992 A1 CA3235992 A1 CA 3235992A1 CA 3235992 A CA3235992 A CA 3235992A CA 3235992 A CA3235992 A CA 3235992A CA 3235992 A1 CA3235992 A1 CA 3235992A1
Authority
CA
Canada
Prior art keywords
compound
group
pharmaceutically acceptable
acceptable salt
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3235992A
Other languages
English (en)
French (fr)
Inventor
Liang Tan
Yuqiong DONG
Min Liu
Jiao LI
Jian Li
Zhen Zhang
Xiaoyan LIN
Yunfei Li
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tuojie Biotech Shanghai Co Ltd
Original Assignee
Tuojie Biotech Shanghai Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tuojie Biotech Shanghai Co Ltd filed Critical Tuojie Biotech Shanghai Co Ltd
Publication of CA3235992A1 publication Critical patent/CA3235992A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA3235992A 2021-11-03 2022-11-03 Substituted phenylpropionic acid derivative and use thereof Pending CA3235992A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202111293711.9 2021-11-03
CN202111293711 2021-11-03
CN202211033065 2022-08-26
CN202211033065.7 2022-08-26
PCT/CN2022/129479 WO2023078333A1 (zh) 2021-11-03 2022-11-03 一种取代的苯丙酸衍生物及其用途一种取代的苯丙酸衍生物及其用途

Publications (1)

Publication Number Publication Date
CA3235992A1 true CA3235992A1 (en) 2023-05-11

Family

ID=86240694

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3235992A Pending CA3235992A1 (en) 2021-11-03 2022-11-03 Substituted phenylpropionic acid derivative and use thereof

Country Status (10)

Country Link
US (1) US20250042847A1 (cg-RX-API-DMAC7.html)
EP (1) EP4428129A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540183A (cg-RX-API-DMAC7.html)
KR (1) KR20240091010A (cg-RX-API-DMAC7.html)
CN (1) CN118055927A (cg-RX-API-DMAC7.html)
AU (1) AU2022381258A1 (cg-RX-API-DMAC7.html)
CA (1) CA3235992A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024005304A (cg-RX-API-DMAC7.html)
TW (1) TW202334116A (cg-RX-API-DMAC7.html)
WO (1) WO2023078333A1 (cg-RX-API-DMAC7.html)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024217537A1 (zh) * 2023-04-21 2024-10-24 深圳信立泰药业股份有限公司 一种叔胺类化合物及其制备方法和医药用途
TW202444710A (zh) * 2023-05-11 2024-11-16 大陸商江蘇恆瑞醫藥股份有限公司 一種脂蛋白化合物晶型及其製備方法
KR20260041098A (ko) * 2023-07-21 2026-03-26 일라이 릴리 앤드 캄파니 Lp(a) 저하 활성을 갖는 피롤리딘 화합물
CN121548567A (zh) * 2023-07-21 2026-02-17 伊莱利利公司 具有Lp(a)降低活性的哌啶、吗啉和四氢哒嗪化合物
CN119490445A (zh) * 2023-08-15 2025-02-21 深圳信立泰药业股份有限公司 一种酰基类化合物及其制备方法和医药用途
CN122535600A (zh) * 2023-11-17 2026-08-07 上海翊石医药科技有限公司 一种取代的2-(吡咯烷-3-基)乙酸的衍生物及其制备方法和用途
CN122270439A (zh) * 2023-11-20 2026-06-23 上海齐鲁制药研究中心有限公司 一种多环类衍生物、其制备方法和应用
WO2025199298A1 (en) 2024-03-21 2025-09-25 Eli Lilly And Company BIOMARKER ASSAY TO MEASURE LIPOPROTEIN(a)
WO2025237188A1 (zh) * 2024-05-14 2025-11-20 石家庄以岭药业股份有限公司 一种LP(a)抑制剂化合物及其应用
CN121627662A (zh) * 2024-09-05 2026-03-10 成都康弘药业集团股份有限公司 芳基丙酸化合物及其制备方法与用途
WO2026061518A1 (zh) * 2024-09-23 2026-03-26 上海京新生物医药有限公司 一种环状胺衍生物的固体形式、制备方法及药物组合物
WO2026119122A1 (zh) * 2024-12-02 2026-06-11 上海喆邺生物科技有限公司 一种苯丙酸衍生物及其医药用途
WO2026130347A1 (zh) * 2024-12-17 2026-06-25 上海喆邺生物科技有限公司 一种吡咯烷衍生物及其在药物中的用途
WO2026130471A1 (zh) * 2024-12-18 2026-06-25 江苏恒瑞医药股份有限公司 吡咯烷衍生物或其盐的制备方法
CN121609698B (zh) * 2026-01-30 2026-06-02 山东京新药业有限公司 一种莫伐培林及中间体的制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1962596A (zh) * 2000-10-11 2007-05-16 埃斯佩里安医疗公司 用于控制胆固醇以及相关用途的酮化合物以及组合物
MXPA03003021A (es) * 2000-10-11 2003-07-14 Esperion Therapeutics Inc Compuestos de eter y composiciones para el control del colesterol y usos relacionados.
US7371777B2 (en) * 2001-08-17 2008-05-13 Eisai Co., Ltd. Cyclic compound and PPAR agonist
AU2003300438A1 (en) * 2003-12-24 2005-08-03 Esperion Therapeutics, Inc. Ether compounds and compositions for cholesterol management and related uses
US7705177B2 (en) * 2003-12-24 2010-04-27 Esperion Therapuetics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US7919506B2 (en) * 2006-03-10 2011-04-05 Pfizer Inc. Dibenzyl amine compounds and derivatives
CA2708706A1 (en) * 2007-12-10 2009-06-18 7Tm Pharma A/S Cannabinoid receptor modulators
KR102720992B1 (ko) 2019-06-07 2024-10-24 일라이 릴리 앤드 캄파니 피롤리딘 화합물
EP4469435A1 (en) * 2022-01-26 2024-12-04 Eli Lilly and Company Pyrrolidine compounds

Also Published As

Publication number Publication date
EP4428129A1 (en) 2024-09-11
JP2024540183A (ja) 2024-10-31
WO2023078333A1 (zh) 2023-05-11
MX2024005304A (es) 2024-05-17
AU2022381258A1 (en) 2024-05-02
US20250042847A1 (en) 2025-02-06
TW202334116A (zh) 2023-09-01
CN118055927A (zh) 2024-05-17
EP4428129A4 (en) 2025-05-07
WO2023078333A8 (zh) 2023-08-10
KR20240091010A (ko) 2024-06-21

Similar Documents

Publication Publication Date Title
EP4428129A1 (en) Substituted phenylpropionic acid derivative and use thereof
JP2025532258A (ja) 大環状誘導体及びその使用
EP4332102A1 (en) Isoquinolone compound and use thereof
EP3980409A1 (en) Pyrrolidine compounds
WO2022038365A2 (en) Novel compounds
CN114206876B (zh) N-甲基,n-(6-(甲氧基)哒嗪-3-基)胺衍生物作为自分泌运动因子(atx)调节剂治疗发炎性气道疾病或纤维化疾病
JP5979230B2 (ja) 含フッ素アミノ酸のプロドラッグ
KR20250128379A (ko) 보체인자 b의 억제제
CN113149902B (zh) 苯甲酰胺类衍生物
KR20200036755A (ko) (-)-시벤졸린 숙신산염의 신규한 제조 공정
JP5983713B2 (ja) 含フッ素アミノ酸のプロドラッグを含有する医薬
CN113121417A (zh) 一种新型哌啶衍生物及其药物用途
US20220204504A1 (en) Deuterated colony stimulating factor-1 receptor (csf-1r) inhibitors
EP4126832B1 (en) Modulators of hemoglobin
JPWO2019059344A1 (ja) 化学活性化型水溶性プロドラッグ
CA3145678C (en) Sglt2/dpp4 inhibitor and application thereof
JP2012211086A (ja) 関節リウマチの治療剤又は予防剤
CN114621189B (zh) 一种内酰胺类衍生物及其用途
RU2819762C1 (ru) Соединение в качестве ингибитора циклинзависимой киназы 9 и его применение
CN101360742A (zh) 具有血清素源性活性和增强的治疗特性的取代苯基哌啶
WO2025045777A1 (en) Inhibitors of pcsk9
WO2026059895A1 (en) Substituted tricyclicheterocyclylsulfonamide derivatives and uses thereof
TW202444709A (zh) 短肽類化合物及其製備方法和醫藥應用
CN118894903A (zh) 一种氨基酸类化合物及其制备方法和医药应用
CN113582988A (zh) 吡啶并环类化合物及其医药用途

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241104

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241104

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241104

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251017

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251017

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20251208

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20251208

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20251208

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE

Effective date: 20251208

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260728